Testing the Addition of Gemcitabine to Usual Treatment (BCG Alone) in People With Recurrent HG NMIBC
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement…
- Investigators
- Paul L Crispen, Padraic O'Malley
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All